Live feed07:00:00·5mPRReleasevia QuantisnowTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental GlomerulosclerosisByQuantisnow·Wall Street's wire, on your screen.TVTX· Travere Therapeutics Inc.Health Care
